NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Hospital das ClÃnicas de Ribeirão Preto
Case Comprehensive Cancer Center
University of Texas Southwestern Medical Center
National Institutes of Health Clinical Center (CC)